HRCM
ALNY icon

Hood River Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Hood River Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-57,565
Closed -$3.64M – 84
2014
Q2 		$3.64M Buy
+57,565
New +$3.42M 0.49% 74

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Hood River Capital Management's ALNY Position: Q3 2014 in Review

Hood River Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2014, closing a stake of 57,565 shares — an estimated $3.64M sold.

Hood River Capital Management first reported a position in ALNY in Q2 2014 and held it in 1 quarter. The position peaked at $3.64M in Q2 2014. 185 funds tracked by Wall St. Rank hold ALNY as of Q3 2014.

  • Hood River Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Hood River Capital Management sold 57,565 Alnylam Pharmaceuticals shares in Q3 2014, an estimated $3.64M.
  • Hood River Capital Management first reported a position in Alnylam Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Hood River Capital Management's Alnylam Pharmaceuticals position peaked at $3.64M in Q2 2014.
  • 185 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2014.

Based on Hood River Capital Management's 13F filing for Q3 2014, filed 4 Nov 2014.